How do you want your Altace be delivered? Choose here!

BALTIMORE, June 11 /PRNewswire/ — Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for Ramipril capsules, 1.25 mg. 2.5 mg, 5 mg and 10 mg. Commercial shipments of the product have commenced.
Lupin’s Ramipril capsules are the AB-rated generic equivalent of King Pharmaceutical’s Altace(R) capsules, indicated for the treatment of hypertension. The brand produ…